Preclinical studies show MGM-15 is approximately 15x (subcutaneous) and 50x (oral) more potent than morphine in rodent models, yet human anecdotal dosing clusters around 25-60 mg oral, roughly 2x the per-milligram potency of 7-hydroxymitragynine. This compound is a rearrangement product of 7-hydroxymitragynine with remarkable μ-opioid receptor affinity (Ki 0.087 nM) and functions as a G-protein biased agonist with minimal β-arrestin-2 recruitment, potentially explaining its reduced respiratory depression and tolerance development compared to morphine. The powder is tan-brown and sparingly soluble in water; volumetric dosing in 95% ethanol or PG:VG solutions is recommended. Duration exceeds that of 7-hydroxymitragynine and kratom leaf, with many users reporting 8-10 hour analgesia. Community harm-reduction recommends keeping 4 mg naloxone readily available and re-dosing every 20-30 minutes if respiratory depression re-emerges.
Also known as: M-p, Pseudo, Mitragynine pseudoindoxyl, Matsumoto MGM-15
Classification
Chemical: Opioid
Chemical: Tryptamine
Psychoactive: Depressant
Psychoactive: Psychedelic
Tag: Alkaloid
Tag: Habit-Forming
Tag: Research-Chemical
Tag: Sedative
Effects
Physical Euphoria
Pain Relief
Sedation
Respiratory Depression
Itchiness
Muscle Relaxation
Cognitive Euphoria
Anxiety Suppression
Compulsive Redosing
Euphoria
Relaxation
Introspection
Dulled Perception
Color Enhancement
Visual Distortion
Auditory Hallucination
Drifting
Visual Acuity Suppression
Routes of Administration
Oral (Toss and Wash / Capsules / Pressed Tabs)
Dosage
Threshold: 7.5 mg
Light: 7.5-20 mg
Common: 20-40 mg
Strong: 40-60 mg
Heavy: 60 mg
Duration
Onset: 0.33-0.75 h
Comeup: 0.5-1 h
Peak: 1-3 h
Offset: 3-5 h
After Effects: 12 h
Sublingual (Powder Held Under Tongue)
Dosage
Threshold: 5 mg
Light: 5-15 mg
Common: 15-30 mg
Strong: 30-50 mg
Heavy: 50 mg
Duration
Onset: 0.17-0.33 h
Comeup: 0.33-0.67 h
Peak: 1-3 h
Offset: 3-5 h
After Effects: 12 h
Insufflated (Rare; Not Recommended)
Dosage
Threshold: 5 mg
Light: 5-10 mg
Common: 10-20 mg
Strong: 20-35 mg
Heavy: 35 mg
Duration
Onset: 0.08-0.17 h
Comeup: 0.25-0.5 h
Peak: 1-2.5 h
Offset: 2-4 h
After Effects: 12 h
Oral
Dosage
Threshold: 5 mg
Light: 5 - 15 mg
Common: 15 - 40 mg
Strong: 40 - 80 mg
Heavy: 80 mg+
Duration
Onset: 0.33-0.5 h
Comeup: 0.5-1 h
Peak: 1-3 h
Offset: 1-2 h
After Effects: 6-24 h
Total Duration: 6-12 h
Sublingual
Dosage
Threshold: 5 mg
Light: 5 - 15 mg
Common: 15 - 40 mg
Strong: 40 - 80 mg
Heavy: 80 mg+
Duration
Onset: 0.17-0.25 h
Comeup: 0.25-0.5 h
Peak: 1-2 h
Offset: 1-2 h
After Effects: 6-24 h
Total Duration: 6-12 h
Rectal
Dosage
Heavy: 60 mg+
Light: 5 - 12 mg
Common: 12 - 30 mg
Strong: 30 - 60 mg
Threshold: 5 mg
Duration
Onset: 0.33-1.5 h
Peak: 1.25-3 h
Offset: 3-6 h
After Effects: 6-24 h
Total Duration: 6-12 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
MGM-15 - Οδηγός ουσίας DrugsPRO
MGM-15: Preclinical studies show MGM-15 is approximately 15x (subcutaneous) and 50x (oral) more potent than morphine in rodent models, yet human anecdotal dosing clusters around 25-60 mg oral, roughly 2x the per-milligram potency of 7-hydroxymitragynine. This compound is a rearrangement product of 7
